Devonian Health Group, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DVHGF research report →
Price Chart
About the company
Devonian Health Group, Inc. is a clinical-stage pharmaceutical company. The firm is engaged in the development of drugs for a range of autoimmune and fibroinflammatory conditions, using novel therapeutic approaches to address unmet medical needs.
- CEO
- Andre Boulet
- IPO
- 2022
- Employees
- 8
- HQ
- Québec, QC, CA
Get TickerSpark's AI analysis on DVHGF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
Latest fiscal year · YoY change
- Revenue
- $17.03M-4.4%
- Gross Profit
- $8.56M+42.9%
- Op Income
- $-1,027,425
- Net Income
- $-4,339,852-254.4%
- EPS
- $-1.76-253.0%
- OCF Growth
- -116.0%
- FCF Growth
- -116.2%
- 52W High
- $10.65
- 52W Low
- $4.27
- 50D MA
- $5.57
- 200D MA
- $8.09
- Beta
- 1.26
- RSI (14)
- 16
- Avg Volume
- 87
No earnings-call transcripts are available for DVHGF yet.
- Free Float
- 87.9%
- Shares Outstanding
- 2.78M
- Float Shares
- 2.44M
Our DVHGF coverage
Recent articles, reports, and earnings notes.
No research on DVHGF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DVHGF report →Devonian Health Group Receives Health Canada Authorization to Evaluate Novel Thykamine™ Formulation for Prevention of Radiation-Induced Skin Injury in Breast Cancer Patients
prnewswire.com · Oct 20
Devonian Health Group Provides Update on its Planned NYSE American Listing
gurufocus.com · Oct 16
Devonian Health Group Provides Update on its Planned NYSE American Listing
prnewswire.com · Oct 16
Devonian Health Group Inc. Anticipates to Commence Trading on the NYSE American
prnewswire.com · Sep 11
Devonian Health Group Strengthens Thykamine™ Manufacturing Platform with Validated Chemical-Composition Fingerprinting and Biological Potency Assay
prnewswire.com · Sep 1
Devonian Health Group Anticipates to Commence Trading on the NYSE American
prnewswire.com · Aug 18
Devonian Health Group Announces Proposed Listing on the NYSE American with Concurrent Underwritten Public Offering
gurufocus.com · Jul 27
Devonian Health Group Announces Proposed Listing on the NYSE American with Concurrent Underwritten Public Offering
prnewswire.com · Jul 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.